COMP <GO>
PRQR vs AKBA // EV/EBITDA & P/E VALUATION
ProQR Therapeutics N.V. (NASDAQ) VS. Akebia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRQR 0
— AKBA 2
■ METRIC PARITY
LAST: $1.39 (-3.47%) • MKT CAP: $203.2M
valuation
—
LAST: $0.71 (-4.81%) • MKT CAP: $205.7M
valuation
4.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRQR VS. AKBA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRQR | AKBA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 85.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 4.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 9.90% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -2.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 47.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.1 | 45.2 | -5.06 | AKBA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $203.2M | $205.7M | -$2.5M | AKBA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRQR REV | AKBA REV | PRQR GROSS % | AKBA GROSS % | PRQR FCF | AKBA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $236.2M | — | 83.3% | — | $67.7M |
| FY 2024 | — | $160.2M | — | 60.6% | — | -$40.7M |
| FY 2023 | — | $194.6M | — | — | — | -$23.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRQR // BETA —
AKBA // BETA —